Woodline Partners’s Inozyme Pharma INZY Stock Holding History

Woodline Partners’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-535,185	Closed	-$2.14M	–	970
2025 Q2	$2.14M	Sell	535,185 -468,554	-47%	-$1.16M	0.01%	713
2025 Q1	$913K	Buy	1,003,739 +615	+0.1%	+$852	0.01%	773
2024 Q4	$2.78M	Hold	1,003,124	–	–	0.02%	599
2024 Q3	$5.25M	Buy	1,003,124 +2,451	+0.2%	+$12.7K	0.04%	384
2024 Q2	$4.46M	Buy	1,000,673 +112,606	+13%	+$546K	0.04%	352
2024 Q1	$6.8M	Buy	888,067 +588,067	+196%	+$3.23M	0.06%	328
2023 Q4	$1.28M	Buy	+300,000	New	+$1.07M	0.01%	397
2023 Q3	–	Sell	-288,827	Closed	-$1.61M	–	667
2023 Q2	$1.61M	Buy	+288,827	New	+$1.71M	0.02%	455

Woodline Partners's INZY Position: Q3 2025 in Review

Woodline Partners sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 535,185 shares — an estimated $2.14M sold.

Woodline Partners first reported a position in INZY in Q2 2023 and held it in 8 quarters. The position peaked at $6.8M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Woodline Partners reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Woodline Partners sold 535,185 Inozyme Pharma shares in Q3 2025, an estimated $2.14M.
Woodline Partners first reported a position in Inozyme Pharma in Q2 2023 and held it in 8 quarters.
Woodline Partners's Inozyme Pharma position peaked at $6.8M in Q1 2024.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.